RU2468800C2 - Комбинированное применение производного простагландина и ингибитора протонового насоса для лечения желудочно-кишечных заболеваний - Google Patents

Комбинированное применение производного простагландина и ингибитора протонового насоса для лечения желудочно-кишечных заболеваний Download PDF

Info

Publication number
RU2468800C2
RU2468800C2 RU2007141655/15A RU2007141655A RU2468800C2 RU 2468800 C2 RU2468800 C2 RU 2468800C2 RU 2007141655/15 A RU2007141655/15 A RU 2007141655/15A RU 2007141655 A RU2007141655 A RU 2007141655A RU 2468800 C2 RU2468800 C2 RU 2468800C2
Authority
RU
Russia
Prior art keywords
hydrogen
halogen
alkyl
derivative
prostaglandin
Prior art date
Application number
RU2007141655/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2007141655A (ru
Inventor
Риюдзи УЕНО
Original Assignee
Сукампо Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сукампо Аг filed Critical Сукампо Аг
Publication of RU2007141655A publication Critical patent/RU2007141655A/ru
Application granted granted Critical
Publication of RU2468800C2 publication Critical patent/RU2468800C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2007141655/15A 2005-04-12 2006-04-11 Комбинированное применение производного простагландина и ингибитора протонового насоса для лечения желудочно-кишечных заболеваний RU2468800C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67023805P 2005-04-12 2005-04-12
US60/670,238 2005-04-12
PCT/JP2006/308001 WO2006109881A1 (en) 2005-04-12 2006-04-11 Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders

Publications (2)

Publication Number Publication Date
RU2007141655A RU2007141655A (ru) 2009-05-20
RU2468800C2 true RU2468800C2 (ru) 2012-12-10

Family

ID=36685683

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007141655/15A RU2468800C2 (ru) 2005-04-12 2006-04-11 Комбинированное применение производного простагландина и ингибитора протонового насоса для лечения желудочно-кишечных заболеваний

Country Status (18)

Country Link
US (1) US8962688B2 (enExample)
EP (1) EP1871380B1 (enExample)
JP (2) JP5711442B2 (enExample)
KR (2) KR101466980B1 (enExample)
CN (1) CN101198334B (enExample)
AU (1) AU2006234632B2 (enExample)
BR (1) BRPI0610557A2 (enExample)
CA (1) CA2602812C (enExample)
DK (1) DK1871380T3 (enExample)
ES (1) ES2371658T3 (enExample)
IL (1) IL186374A (enExample)
NO (1) NO20075764L (enExample)
NZ (1) NZ562763A (enExample)
PL (1) PL1871380T3 (enExample)
PT (1) PT1871380E (enExample)
RU (1) RU2468800C2 (enExample)
WO (1) WO2006109881A1 (enExample)
ZA (1) ZA200709072B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2379652T3 (es) * 2002-10-23 2012-04-30 Sucampo Ag Compuestos de prostaglandina para el tratamiento de obesidad
US7868045B2 (en) * 2006-09-06 2011-01-11 Sucampo Ag Method for promoting gastrointestinal bicarbonate secretion
US20090012165A1 (en) * 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
WO2009157397A1 (ja) * 2008-06-23 2009-12-30 日本新薬株式会社 非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤
US20110034424A1 (en) * 2009-06-30 2011-02-10 Sucampo Ag Method for the long term nsaid use
AU2012246999A1 (en) * 2011-04-19 2013-10-17 Sucampo Ag Method for modulating cytokine activity
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
KR20160015100A (ko) 2014-07-30 2016-02-12 미래파인켐 주식회사 프로스타글란딘 중간체의 제조방법
KR20170025682A (ko) 2015-08-31 2017-03-08 미래파인켐 주식회사 프로스타글란딘 유도체의 신규한 제조방법
CN107582556A (zh) * 2017-09-15 2018-01-16 成都泠汐尚品科技有限公司 一种治疗消化性溃疡的药物复方制剂
CN108051553A (zh) * 2017-12-29 2018-05-18 武汉轻工大学 一种仔猪肠道功能保护剂的筛选方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
WO2000035448A1 (en) * 1998-12-14 2000-06-22 Astrazeneca Ab New pharmaceutical formulation
WO2001076593A2 (en) * 2000-04-06 2001-10-18 Sucampo Ag Bile secretion promoting composition a 15-keto prostaglandin
WO2002089812A1 (en) * 2001-05-02 2002-11-14 Sucampo Ag Composition for treating drug-induced constipation with 15-keto-prostaglandins
WO2004060377A1 (en) * 2002-12-27 2004-07-22 Sucampo Ag Derivatives of prostaglandins for treating abdominal discomfort

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380709A (en) 1987-01-28 1995-01-10 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
US5225439A (en) 1987-01-28 1993-07-06 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti ulcers containing same
JPH0688966B2 (ja) * 1987-01-28 1994-11-09 株式会社アールテック・ウエノ プロスタグランジンｅ類およびそれを含む抗潰瘍剤
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
TW249226B (enExample) 1990-04-04 1995-06-11 Aderk Ueno Kk
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
KR19990036322A (ko) 1996-06-10 1999-05-25 류지 우에노 엔도텔린길항제
ATE402925T2 (de) 1999-10-15 2008-08-15 Sucampo Ag Neue zusammensetzung enthaltend eine bicyclische verbindung und ein glycerid
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
JP4786866B2 (ja) 2001-08-31 2011-10-05 スキャンポ・アーゲー クロライドチャンネルオープナーとしてのプロスタグランジンアナログ
AR037524A1 (es) 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
US7732487B2 (en) 2001-11-19 2010-06-08 Sucampo Ag Method for treating a disease or condition responsive to opening of C1C-2 channel
AU2004206141A1 (en) 2003-01-24 2004-08-05 Niva Shapira Synergistic compositions and methods for potentiating anti-oxidative activity
TWI367759B (en) 2003-02-20 2012-07-11 Santarus Inc A novel formulation, omeprazole antacid complex-immediate release, for rapid and sustained suppression of gastric acid

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
WO2000035448A1 (en) * 1998-12-14 2000-06-22 Astrazeneca Ab New pharmaceutical formulation
WO2001076593A2 (en) * 2000-04-06 2001-10-18 Sucampo Ag Bile secretion promoting composition a 15-keto prostaglandin
WO2002089812A1 (en) * 2001-05-02 2002-11-14 Sucampo Ag Composition for treating drug-induced constipation with 15-keto-prostaglandins
WO2004060377A1 (en) * 2002-12-27 2004-07-22 Sucampo Ag Derivatives of prostaglandins for treating abdominal discomfort

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HIXSON L.J. «Current trends in the pharmacotherapy for peptic ulcer disease» Archives of internal medicine, 1992, (152(4)), 726-732. *
McCOLL K.E.L. «Assessment of two new therapies for peptic ulcer disease omeprazole and the prostaglandin analogues» Digestive Diseases, 1988, 6(2), 65-75. *
McCOLL K.E.L. «Assessment of two new therapies for peptic ulcer disease omeprazole and the prostaglandin analogues» Digestive Diseases, 1988, 6(2), 65-75. HIXSON L.J. «Current trends in the pharmacotherapy for peptic ulcer disease» Archives of internal medicine, 1992, (152(4)), 726-732. *
ДАЙСОН Г., МЕЙ П. Химия синтетических лекарственных веществ, пер. с англ. - М.: Мир, 1964, с.12-19. МАШКОВСКИЙ М.Д. Лекарственные средства. - М.: Новая волна, 2001, т.1, с.11. *

Also Published As

Publication number Publication date
EP1871380B1 (en) 2011-10-19
WO2006109881A1 (en) 2006-10-19
EP1871380A1 (en) 2008-01-02
NO20075764L (no) 2008-01-14
KR20140069182A (ko) 2014-06-09
CA2602812C (en) 2014-11-18
US20070276006A1 (en) 2007-11-29
RU2007141655A (ru) 2009-05-20
AU2006234632B2 (en) 2011-10-27
ES2371658T3 (es) 2012-01-05
JP5711442B2 (ja) 2015-04-30
BRPI0610557A2 (pt) 2010-06-29
IL186374A (en) 2013-05-30
JP2013121972A (ja) 2013-06-20
IL186374A0 (en) 2008-03-20
DK1871380T3 (da) 2011-11-21
JP2008535774A (ja) 2008-09-04
KR101466980B1 (ko) 2014-12-01
ZA200709072B (en) 2008-11-26
PT1871380E (pt) 2011-11-21
PL1871380T3 (pl) 2012-03-30
CN101198334B (zh) 2013-02-06
KR20070119753A (ko) 2007-12-20
CN101198334A (zh) 2008-06-11
NZ562763A (en) 2010-12-24
US8962688B2 (en) 2015-02-24
AU2006234632A1 (en) 2006-10-19
CA2602812A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
JP2013121972A (ja) 胃腸障害の処置のためのプロスタグランジン化合物およびプロトンポンプ阻害剤の併用
EP2175861B1 (en) Pharmaceutical combination of naproxen with 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E1
JP6408426B2 (ja) 胃腸障害処置用プロスタグランジン誘導体
ES2368729T3 (es) Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento del estreñimiento.
CN1753680B (zh) 用于治疗腹部不适的前列腺素衍生物
JP5427029B2 (ja) 消化管の重炭酸分泌を促進するための方法および組成物
US10561649B2 (en) Pharmaceutical combination of opioid and prostaglandin compound
RU2392941C2 (ru) Производные простагландинов для лечения желудочно-кишечного нарушения
RU2445961C2 (ru) Способ и композиция для лечения повреждений слизистых оболочек

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20180412